Last reviewed · How we verify
HepA-L
HepA-L, developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, though specific revenue figures are not available. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | HepA-L |
|---|---|
| Sponsor | Institute of Medical Biology, Chinese Academy of Medical Sciences |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
- Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome (PHASE4)
- Phase IV Study of Concomitant Administration of the sIPV and HepA (PHASE4)
- Epigenetic Effects of Diesel Exhaust and Ozone Exposure (NA)
- Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HepA-L CI brief — competitive landscape report
- HepA-L updates RSS · CI watch RSS
- Institute of Medical Biology, Chinese Academy of Medical Sciences portfolio CI